UPDATE: Morgan Stanley Starts Nautilus Biotechnology (NAUT) at Equalweight

Morgan Stanley analyst Tejas Savant initiates coverage on Nautilus Biotechnology (NASDAQ: NAUT) with a Equalweight rating and a price target of $8.00.

The analyst comments "While NAUT is developing a highly disruptive proteomics platform with significant long-term growth potential, the story remains in its early innings; we see limited room for NTM relative upside in the stock, with the broad commercial launch not expected until the late ‘23/early ’24 timeframe."

For an analyst ratings summary and ratings history on Nautilus Biotechnology click here. For more ratings news on Nautilus Biotechnology click here.

Shares of Nautilus Biotechnology closed at $4.85 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30